Evidence map›Paper›PMID 36944461›Full record

ArticleBMJ open2023

CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine-citrate-heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients.

Ceder Hildegard van den Bosch, Yvette Loeffen, Alida F W van der Steeg, Jan-Tom T van der Bruggen, Florine N J Frakking, Marta Fiocco, Cornelis P van de Ven, Marc H W A Wijnen, Marianne D van de Wetering

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05740150 (The Efficacy of a Lock Solution Containing Taurolidine, Citrate and Heparin for the Prevention of Tunneled Central Line-associated Bloodstream Infections in Pediatric Oncology Patients, a Randomized Controlled, Mono-center Trial.), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05740150 naunknown statusnot on this map

The Efficacy of a Lock Solution Containing Taurolidine, Citrate and Heparin for the Prevention of Tunneled Central Line-associated Bloodstream Infections in Pediatric Oncology Patients, a Randomized Controlled, Mono-center Trial.

TypeinterventionalSponsorPrincess Maxima Center for Pediatric OncologyRan2020 to 2023Enrolled462ConditionsCentral Line-associated Bloodstream Infection (CLABSI)ArmsTauroLock-Hep100 (taurolidine 1.35%, citrate 4%, heparin 100 IU/mL), Heparin lock (heparin 100 IU/mL)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Impact of TauroLockEuropean journal of medical research · 2025
    Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Ceder Hildegard van den BoschPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands c.h.vandenbosch-4@prinsesmaximacentrum.nl.ORCID 0000-0003-0612-578X
Yvette LoeffenDepartment of Pediatric Infectious Diseases and Immunology, UMC Utrecht, Utrecht, The Netherlands.
Alida F W van der SteegPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Jan-Tom T van der BruggenDepartment of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Florine N J FrakkingDepartment of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Marta FioccoPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Cornelis P van de VenPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marc H W A WijnenPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marianne D van de WeteringPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Princess Máxima Center · NLUniversity Medical Center Utrecht · NLLeiden University · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe efficacy of taurolidine containing lock solutions for the prevention of central line-associated bloodstream infections (CLABSI) in paediatric oncology patients is still unknown. If the taurolidine-citrate-heparin lock appears to decrease the incidence of CLABSIs, we hope to increase the quality of life of children with cancer by subsequently reducing the central venous access device (CVAD)-removal rates, dispense of antibiotics, hospital admissions and incidence of severe sepsis resulting in intensive care unit admission. METHODS AND ANALYSIS: This assessor-blinded randomised controlled trial including 462 patients was designed to compare the taurolidine-citrate-heparin lock to the heparin-only lock for the prevention of CLABSIs in paediatric oncology patients. Patients receiving their first CVAD at the Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands, are eligible for inclusion. The primary outcome of this study is the incidence of first CLABSIs from CVAD insertion until the end of the study, maximum follow-up of 90 days. An intention-to-treat and a per-protocol analysis will be performed. An interim analysis will be performed after the inclusion of 50% of the patients. The results of the interim analysis and overall conduct of the trial will be discussed by a data safety monitoring board. ETHICS AND DISSEMINATION: The medical ethics committee NedMec, Utrecht, the Netherlands, has approved this research (number 20/370). Written informed consent for participation in this trial and publication of the trial data is obtained from all patients and/or their parents/guardians. The results of this trial will be published in a peer-reviewed journal and the data will be made available on reasonable request after publication of the main results manuscript. TRIAL REGISTRATION NUMBERS: NTR6688; NCT05740150.

Indexed as

Catheter-Related InfectionsCentral Venous CathetersNeoplasmsSepsisChildCitratesCitric AcidHeparinHumansQuality of LifeRandomized Controlled Trials as TopicTaurineThiadiazinesCitratesCitric AcidHeparinTaurinetaurolidineThiadiazinesInfection controlPaediatric oncologyPREVENTIVE MEDICINE

Identifiers

PMID36944461
PMCPMC10032404
OpenAlexW4353015383

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.